Contineum Therapeutics, Inc. (CTNM) Q3 2025 Earnings Call

Concluded Oct 30, 2025

Oct 30, 2025 0 turns

Period: FY2025 Q3
Runtime: —
Sources: 2 artifacts

Net income -$12.79M

Open full screen 8-K 10-Q

Executive readout · one minute

Webcast research workspace

Read the call alongside every captured source. 8-K earnings release, 10-Q stay in one workspace.

LPA1 / Pipe791 IPF Differentiation 61 Propel IPF Phase 2 Trial 38 BMS Milperant Phase 3 Readout 15 MDD / Moonlight 1 with J&J 13 Pain Program (Osteoarthritis / Lower Back Pain) 9 J&J Partnership Economics 5

Management tone

Confident

Net tone +72 · low hedging

Grounding quotes

“This is a catalyst-rich year for us.”
“the biggest takeaway out of this study”
“really gives us a lot of confidence that this is a safe and tolerable, it's a compound that should be tested further due to the safety and tolerability that we've seen already.”
“we're hopeful for data in the second half of the year”

Research coverage

2 live sources

Open each available source without leaving this research workspace.

Research materials

Open the source you need; every reader stays inside this workspace.

8-K earnings release Filed Oct 30, 2025 10-Q report Filed Oct 30, 2025

Read transcripts like this one from Claude, ChatGPT or your own code with the earnings call transcript API →